Last-Resort cancer drug made available to patients before approval
NCT ID NCT07215832
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers early access to the investigational drug selinexor for people with certain advanced cancers, such as multiple myeloma, lymphoma, sarcoma, and others, who have no other treatment options. Patients must not qualify for any ongoing clinical trial and must have exhausted all available therapies. The drug is provided through their treating physician, who must obtain regulatory approval.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
selinexor
What this could lead to
If successful, this program could provide early access to a potential treatment for patients with advanced cancers who have run out of options.
What could go wrong
This is an expanded access program, not a clinical trial, so effectiveness and safety are still being studied. The drug may not work for everyone and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••